相关实验视频

Updated: Jun 29, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

HER2 (ERBB2) 改变非小细胞肺癌的临床病理和分子特征:对精准医学的影响

Yurimi Lee¹, Boram Lee², Yoon-La Choi³

¹Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Pathology, Chungnam National University College of Medicine, Daejeon, South Korea.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

|April 8, 2024

概括

在非小细胞肺癌 (NSCLC) 中的人类表皮生长因子受体2 (HER2) 改变是复杂的. 下一代测序对于识别HER2突变和指导NSCLC患者的向治疗至关重要.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
分子生物学分子生物学

背景情况:

人类表皮生长因子受体2 (HER2) 表达,放大和突变在非小细胞肺癌 (NSCLC) 中的作用尚未完全理解.
在NSCLC中发现HER2变化的最佳检测方法需要进一步的研究.

研究的目的:

描述HER2变异性NSCLC的临床病理和分子特征.
评估用于识别可能从HER2向治疗中受益的NSCLC患者的实际方法.

主要方法:

下一代测序 (NGS) 用于分析1680名NSCLC患者.
审查了临床病理学数据和组织幻灯片.
进行了免疫组织化学 (IHC) 和白银在位杂交.

主要成果:

在5.3%的NSCLC患者中发现了HER2的改变 (放大或突变).
HER2氨酸激酶域 (TKD) 突变,主要是20个外子插入,与特定的临床病理特征和低生存率有关.
通过IHC和in situ杂交,HER2的变异表现出异质的模式,通常与其他可操作的突变同时发生.

结论:

NGS对于检测NSCLC中的HER2突变至关重要,特别是当其他分子变化存在时.
临床病理特征和HER2 IHC结果可以帮助识别患有HER2变异NSCLC的患者.
这些发现支持对HER2变异性NSCLC进行改进的诊断和治疗策略.

关键词:

在HER2放大时,HER2放大.这是一个HER2突变.这是下一代测序.不是小细胞肺癌的肺癌氨酸激酶域突变突变

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...